'In­spired' by Ipsen's mis­sion, San­dra Sil­vestri joins as next CMO; Ex­i­cure's slide con­tin­ues with CEO, CFO ex­its

Ipsen is wait­ing on an FDA de­ci­sion this sum­mer for what could be the first drug to treat an ul­tra-rare bone dis­ease called fi­brodys­pla­sia os­si­f­i­cans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.